sex, fertility, pregnancy, and mental health

these are the questions people type at 2am and never say to a face: the antidepressant that fixed your mood and took your sex life, the desire that went and did not come back, the fourteenth month of a fertility calendar, the miscarriage nobody knew about, the baby you love and the dread you cannot explain.

what is currently online for all of it is clinical boilerplate or a forum thread from 2013. this is the third option: what the research actually found, in plain language, with every citation checked and every limitation stated — including the studies whose conclusions are weaker than their reputations.

32 studies sit behind these pages. every one was fetched from its source record, checked for retractions, and had its funding read literally or recorded as unknown.

low libido and mental health

the single most useful finding here is that the traffic runs both ways. pooling prospective cohort studies, depression raised the later risk of sexual dysfunction (adjusted RR/OR 1.71, 95% CI 1.05 to 2.78, six studies in 3,285 people followed 2–9 years) — and sexual dysfunction raised the later odds of depression more strongly still (adjusted OR 3.12, 95% CI 1.66 to 5.85, six studies in 11,171 people followed 1–10 years)^[1].

low desire is not simply a symptom of depression that resolves when the mood lifts. it also predicts depression. treating one and ignoring the other is a choice with consequences.

the limitations are real: only eight citations survived screening, the depression-to-dysfunction association lost significance in the partially adjusted model until an outlying study was removed, and prospective cohorts show sequence rather than causation.

most low desire is not a disorder

in 31,581 US women drawn from a nationally representative panel, 43.1% reported some sexual problem — but only 12.0% reported a sexual problem plus personal distress about it^[2]. distressing problems peaked in midlife (14.8% at ages 45–64 versus 10.8% younger and 8.9% older), and depression and anxiety were among the correlates.

that gap between 43.1% and 12.0% is the whole point. the distress is what makes it a problem, and headline prevalence figures of this kind have been used commercially to size markets for desire drugs — a reason to read the distress threshold rather than the big number.

and when it is a problem, depression is often in the room

re-analysing the same 31,581 women after accounting for concurrent depression, the population prevalence of a distressing desire disorder fell from 10.0% to 6.3% once women with current depression were excluded — meaning roughly 40% of women with a desire, arousal or orgasm disorder also had depression at the same time^[3]. the same pattern held for arousal and orgasm.

the authors are explicit that because the study is cross-sectional, “causality versus comorbidity cannot be determined”. it is overlap, not proof that depression causes low desire — and depression was defined partly by antidepressant use, which itself lowers desire, so the two exposures are entangled. see the SSRI page for that half of it.

what worked in a trial

148 women with sexual interest/arousal disorder were randomised to eight weekly sessions of group mindfulness-based cognitive therapy or group supportive sex education. desire and arousal improved with large effect sizes (d = −1.29 to −1.60) and stayed improved at 12 months. about half of participants across both treatments reported moderate or great improvement^[4].

the honest reading: both arms improved equally. mindfulness beat sex education only on sexual distress (d = 0.83 to 1.17), relationship satisfaction and rumination about sex. so this is not evidence that mindfulness specifically works — it is evidence that eight weeks of structured group attention works. there was no waitlist arm to rule out regression to the mean, and all 148 participants were cisgender women.

sexual performance anxiety

this section is short for a reason that is itself the finding. we could not find a single randomised trial in which sexual performance anxiety was the enrolment diagnosis and the treatment target. searches returned prevalence surveys, narrative reviews, and trials that enrolled people by dysfunction — erectile dysfunction, premature ejaculation, low desire — rather than by the anxiety itself.

the review that estimates its prevalence puts it at 9–25% of men — contributing to premature ejaculation and psychogenic erectile dysfunction — and 6–16% of women, where it severely inhibits desire. its central finding is an absence: there is no recognised diagnosis in either sex, and consequently, in the author’s words, “research into treatment has been minimal”. CBT and mindfulness are recommended by extrapolation from non-sexual performance and social anxiety^[5].

what exists instead: therapy for the dysfunction

across 20 randomised trials from 1980 to 2009 comparing a psychological treatment with a waitlist, symptom severity improved by d = 0.58 (95% CI 0.40 to 0.77) and sexual satisfaction by d = 0.47 (95% CI 0.27 to 0.70). evidence was good for female hypoactive sexual desire disorder and female orgasmic disorder and thin everywhere else, and of 14 head-to-head comparisons the effect sizes ran from d = −0.69 to 2.29 — meaning nobody knows which therapy is best^[6]. every pooled effect is against a waitlist, so attention and expectancy are baked into it, and the search ends before internet-delivered treatment existed.

for erectile dysfunction specifically, a Cochrane review pooled 11 randomised or quasi-randomised trials in 398 men: group psychotherapy reduced persistent erectile dysfunction versus waitlist (RR 0.40, 95% CI 0.17 to 0.98), still present at six months, and adding group therapy to sildenafil beat sildenafil alone (RR 0.46, 95% CI 0.24 to 0.88) while cutting dropout (RR 0.29, 95% CI 0.09 to 0.93)^[7]. the trials are old, tiny and mostly at the edge of significance — this supports offering therapy alongside a drug, not instead of one.

and if sitting in a room to discuss it is the barrier: 98 heterosexual men were randomised to internet-delivered sex therapy with no face-to-face contact, or to a waitlist. 48% reported their sexual functioning much or somewhat improved — but in the erectile-dysfunction group the overall treatment effect only approached significance (P = 0.065), and in the premature-ejaculation group the treatment was not better than the waitlist at all^[8].